CDSCO Loan Licence Consultant for Pharma Manufacturers helps pharmaceutical companies, startups, brand owners, marketers, and businesses manufacture drugs using the facilities of an existing licensed pharmaceutical manufacturer instead of establishing their own manufacturing plant immediately.
A Drug Loan Licence can be useful for companies that have their own product portfolio and marketing network but want to use another manufacturer's approved premises, machinery, technical staff, quality-control facilities, and manufacturing infrastructure.
The licence is regulated under the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945. Depending on the drug category, the application is generally handled by the concerned State Licensing Authority, while CDSCO involvement may arise for new drugs, certain biological products, vaccines, and other centrally regulated categories.
A CDSCO Loan Licence Consultant can help determine the correct regulatory pathway, identify a suitable manufacturing facility, prepare documentation, review GMP compliance, coordinate product permissions, prepare the application, support inspection readiness, and respond to regulatory queries.
What is a Drug Loan Licence?
A Drug Loan Licence allows an applicant who does not have its own manufacturing facilities to use the manufacturing facilities of another licensed pharmaceutical manufacturer.
In simple terms:
Brand / Pharma Company → Approved Third-Party Manufacturing Facility → Loan Licence → Manufacture of Approved Products
The applicant obtains its own regulatory permission while manufacturing is carried out at the approved premises of another manufacturer.
The arrangement is different from simply purchasing finished pharmaceutical products from a third-party manufacturer.
Who Can Apply for a Pharma Loan Licence?
A Loan Licence may be useful for:
- Pharmaceutical startups
- Pharma marketing companies
- Brand owners
- New pharmaceutical businesses
- Existing pharma companies expanding product portfolios
- Companies without their own manufacturing plant
- Businesses entering new dosage forms
- Companies outsourcing production
- Pharmaceutical exporters
- Healthcare businesses launching branded medicines
A business should assess the proposed products, manufacturing facility, technical capabilities, and applicable licensing route before applying.
Why Pharma Companies Choose a Loan Licence
Setting up a pharmaceutical manufacturing plant can require substantial investment in:
- Land
- Civil construction
- Production machinery
- HVAC
- Water systems
- Quality-control laboratory
- Utilities
- Technical personnel
- GMP systems
- Validation
- Environmental approvals
A Loan Licence allows a business to enter manufacturing without initially developing all this infrastructure independently.
Potential benefits include:
- Lower initial capital investment
- Faster market entry
- Access to established manufacturing facilities
- Use of existing machinery
- Existing quality-control infrastructure
- Access to experienced technical staff
- Ability to expand product portfolio
- Lower infrastructure risk
However, obtaining a Loan Licence does not remove the applicant's regulatory responsibilities.
Drug Loan Licence vs Third-Party Manufacturing
These two arrangements are often confused.
Under a third-party manufacturing arrangement, a licensed manufacturer produces medicines for another company's brand according to the applicable regulatory structure.
Under a Loan Licence, the applicant itself obtains a licence to manufacture specified drugs using the facilities of another licensed manufacturer.
The appropriate model depends on:
- Business structure
- Product ownership
- Manufacturing responsibility
- Regulatory strategy
- Product approvals
- Commercial arrangement
A regulatory assessment should be completed before signing a manufacturing agreement.
Common Loan Licence Forms for Pharma Manufacturing
The applicable application form depends on the drug category.
For many conventional drugs other than certain specialised categories, the commonly used route is:
Form 24A → Application for Loan Licence
Form 25A → Loan Licence
For applicable drugs covered under Schedule C and Schedule C(1), a different regulatory route may apply, commonly involving:
Form 27A → Application
Form 28A → Loan Licence
Special categories of drugs may require separate permissions or forms.
The exact licence should therefore be confirmed according to the proposed product list before filing.
Role of CDSCO in Pharma Loan Licence Applications
Many conventional drug manufacturing licences and Loan Licences are administered by the concerned State Licensing Authority.
However, CDSCO may become relevant where the proposed products involve areas such as:
- New drugs
- Vaccines
- Biological products
- Recombinant products
- Certain specialised formulations
- Products requiring Central Licensing Authority approval
Therefore, the actual compliance route may involve:
State Loan Licence + CDSCO Permission, where applicable
The product regulatory status should be checked before the application is prepared.
Role of a CDSCO Loan Licence Consultant
A consultant can assist with:
- Drug category assessment
- Loan Licence applicability
- Product regulatory status
- Form selection
- Host manufacturer assessment
- Manufacturing capacity review
- Schedule M GMP assessment
- Product documentation
- Technical staff review
- Quality-control facility review
- Manufacturing agreement documentation
- Application preparation
- Regulatory filing
- Inspection preparation
- Query-response support
- Product endorsement
- Post-approval compliance
The objective is to ensure that both the Loan Licence applicant and host manufacturing facility meet the applicable requirements.
Choosing the Right Pharma Manufacturing Facility
Selecting the host manufacturer is one of the most important steps.
The proposed manufacturer should have suitable facilities for the dosage form and products intended under the Loan Licence.
The assessment should consider:
- Valid manufacturing licence
- Approved dosage form
- GMP compliance
- Production capacity
- Machinery
- Quality-control laboratory
- Technical staff
- Storage facilities
- Validation systems
- Previous regulatory history
A facility licensed only for tablets cannot automatically be assumed suitable for sterile injections or another specialised dosage form.
Available Manufacturing Capacity
The Licensing Authority may evaluate whether the host manufacturer has sufficient capacity to manufacture products on behalf of the Loan Licence applicant.
The review can include:
- Existing production load
- Number of products
- Machinery capacity
- Manufacturing schedule
- Quality-control capacity
- Storage
- Personnel
The host facility should have adequate infrastructure without compromising its existing licensed manufacturing operations.
Schedule M GMP Compliance
The manufacturing premises used under a Loan Licence should comply with applicable pharmaceutical Good Manufacturing Practices (GMP) requirements.
Important areas can include:
- Pharmaceutical Quality System
- Personnel
- Premises
- Equipment
- Material management
- Production
- Quality assurance
- Quality control
- Documentation
- Validation
- Complaints
- Product recall
- Change control
- CAPA
- Self-inspection
The revised Schedule M framework has increased the importance of structured quality systems for pharmaceutical manufacturing.
A pre-application GMP gap assessment can therefore be useful.
Product Assessment Before Loan Licence Filing
Every proposed drug should be reviewed before inclusion in the application.
The assessment may consider:
- Generic name
- Brand name
- Composition
- Strength
- Dosage form
- Pharmacological category
- Schedule classification
- New drug status
- Manufacturing process
- Test specifications
A company should avoid applying for products that the host facility cannot manufacture or test appropriately.
New Drug Approval and Loan Licence
A Loan Licence by itself does not automatically authorise manufacture of a product that separately requires new drug permission.
If the product falls within the applicable definition of a new drug, additional CDSCO permission may need to be obtained.
The regulatory assessment should review:
- Active ingredient
- Strength
- Dosage form
- Route of administration
- Combination
- Indication
- Regulatory history
The Loan Licence application and new drug approval strategy should be coordinated where both apply.
Documents Required for Pharma Loan Licence
The exact documentation varies according to state, product category, and dosage form.
Common documents may include:
- Certificate of Incorporation
- PAN
- GST Registration
- Applicant address proof
- Director or authorised signatory documents
- Host manufacturer's manufacturing licence
- Manufacturing premises details
- Product list
- Product compositions
- Manufacturing agreement
- Consent letter from host manufacturer
- Manufacturing-process details
- Machinery list
- Quality-control equipment
- Technical staff details
- GMP documents
- Product specifications
- Testing methods
- Label drafts
- New drug approval, where applicable
- Other documents requested by the Licensing Authority
The applicant and host manufacturer should ensure consistency across all submitted documents.
Manufacturing Agreement
A clear agreement between the Loan Licence applicant and manufacturing facility is important.
The agreement may define:
- Products to be manufactured
- Production responsibilities
- Raw-material responsibilities
- Quality-control responsibility
- Batch release
- Packaging
- Storage
- Documentation
- Recall responsibilities
- Complaint handling
- Regulatory compliance
- Confidentiality
- Record access
Commercial arrangements should not conflict with regulatory responsibilities.
Quality Control Requirements
Products manufactured under a Loan Licence need proper testing and release.
The host facility should have suitable testing arrangements for:
- Raw materials
- Packaging materials
- In-process samples
- Finished products
- Stability, where applicable
- Microbiological parameters, where applicable
The laboratory should be suitable for the proposed products.
Records should demonstrate that each batch meets its approved specification before release.
Loan Licence Application Process
A practical Loan Licence application can generally be divided into the following stages.
Step 1: Finalise Product List
Prepare the list of drugs proposed for manufacture.
Review:
- Composition
- Dosage form
- Strength
- Regulatory category
- New drug status
This determines the licensing pathway.
Step 2: Select Host Manufacturer
Identify a licensed pharmaceutical facility with suitable:
- Dosage-form approval
- Machinery
- Capacity
- GMP systems
- Laboratory
- Technical staff
The facility should be reviewed before the commercial agreement is finalised.
Step 3: Conduct Regulatory Gap Assessment
The consultant reviews both parties' documents and identifies gaps relating to:
- Existing licences
- Product permissions
- GMP
- Technical staff
- Manufacturing capability
- Quality control
- Documentation
Gaps should preferably be corrected before filing.
Step 4: Prepare Manufacturing Agreement
A formal agreement or consent arrangement is prepared between the applicant and host manufacturer.
The responsibilities of both parties should be clearly defined.
Step 5: Prepare Loan Licence Application
The appropriate application is prepared according to the drug category.
For commonly applicable conventional drug categories, this can include Form 24A.
Supporting documents are compiled and checked.
Step 6: Submit Application
The application is submitted to the competent Licensing Authority through the applicable state or online regulatory process.
The authority may review:
- Applicant
- Products
- Host manufacturer
- Manufacturing capacity
- GMP status
- Technical personnel
- Quality-control facilities
Step 7: Regulatory Inspection
Depending on the application and regulatory requirements, the manufacturing facility may be inspected.
The inspection may evaluate:
- Manufacturing area
- Machinery
- GMP systems
- Quality-control laboratory
- Documentation
- Product capability
- Technical personnel
- Storage facilities
The host facility should be inspection-ready.
Step 8: Respond to Regulatory Queries
Queries may relate to:
- Product composition
- Facility capacity
- Machinery
- GMP documents
- Technical staff
- Quality control
- Manufacturing agreement
- Product regulatory status
Responses should be submitted with appropriate supporting documentation.
Step 9: Grant of Loan Licence
After satisfactory review, the Licensing Authority may grant the Loan Licence for the approved:
- Applicant
- Manufacturing premises
- Dosage forms
- Products
Commercial manufacture should remain within the approved scope.
Loan Licence for Tablet Manufacturing
Loan Licence arrangements are commonly considered for pharmaceutical formulations such as tablets.
The host facility should have appropriate:
- Dispensing
- Granulation
- Compression
- Coating, where applicable
- Packing
- Quality testing
The proposed tablet products should be compatible with the facility's licensed manufacturing scope.
Loan Licence for Capsules
Capsule manufacturing may require suitable facilities for:
- Blending
- Capsule filling
- Inspection
- Packing
- Quality control
The host manufacturer's existing licence and machinery should cover the proposed dosage form.
Loan Licence for Syrups and Liquid Formulations
Liquid oral products may require:
- Purified water system
- Mixing vessels
- Storage tanks
- Filling equipment
- Packaging equipment
- Microbiological controls
The regulatory review should ensure that the host plant has adequate capacity and controls.
Loan Licence for Sterile Products
Sterile pharmaceutical manufacturing requires significantly more stringent controls.
Products such as injections may require:
- Clean rooms
- HVAC
- Sterilisation systems
- Aseptic processing
- Environmental monitoring
- Water for Injection systems
- Microbiology laboratory
- Validation
A sterile Loan Licence application should therefore involve a detailed facility assessment before filing.
Product Addition to Existing Loan Licence
A company with an existing Loan Licence may later wish to add:
- New products
- New strengths
- New dosage forms
- New combinations
The applicable endorsement or permission should be obtained before commercial manufacture of products not already covered.
The consultant should check whether additional regulatory approvals are required for the new product.
Can a Loan Licence Be Used at Multiple Factories?
A Loan Licence is linked to the approved manufacturing arrangement and premises.
If a company wants to manufacture products at another facility, the regulatory implications should be assessed separately.
A licence for one host manufacturing site should not automatically be assumed to cover another factory.
Pharma Loan Licence and Trademark
The brand name and trademark may belong to the Loan Licence applicant while manufacturing takes place at another licensed facility.
Businesses should maintain clarity regarding:
- Brand owner
- Manufacturer
- Marketer
- Loan Licence holder
- Product label
The label should correctly identify the legally required parties.
Labelling of Products Manufactured Under Loan Licence
Product labels should comply with applicable drug labelling requirements.
Depending on the product, information may include:
- Product name
- Composition
- Strength
- Batch number
- Manufacturing date
- Expiry date
- Manufacturing licence details
- Manufacturer details
- Storage conditions
- Schedule warning
- MRP
- Other required declarations
Label artwork should be reviewed before commercial printing.
Loan Licence vs Own Manufacturing Plant
A Loan Licence may be suitable when the company wants:
- Faster market entry
- Lower initial CAPEX
- Limited product volumes
- Market testing
- Expansion without a new factory
An own manufacturing plant may become more suitable when:
- Production volume is large
- Product portfolio is extensive
- Manufacturing technology is proprietary
- Greater process control is required
- Long-term manufacturing scale justifies investment
The better option depends on the company's commercial strategy.
Environmental Compliance and Loan Licence
The host manufacturing facility remains subject to applicable environmental approvals.
Depending on its manufacturing activity, these may include:
- Consent to Establish
- Consent to Operate
- Hazardous Waste Authorisation
- ETP compliance
- Air pollution-control requirements
- Factory Licence
- Fire approvals
The manufacturing facility's environmental approvals should support the activities undertaken at the premises.
Common Mistakes in Pharma Loan Licence Applications
Common issues include:
- Selecting an unsuitable host manufacturer
- Applying for products outside the facility's approved scope
- Insufficient manufacturing capacity
- Missing GMP documentation
- Incorrect licence form
- Incomplete manufacturing agreement
- Ignoring new drug status
- Technical staff deficiencies
- Inadequate quality-control facilities
- Product composition mismatch
- Incorrect labels
- Manufacturing before licence approval
- Adding products without endorsement
A pre-application review can reduce these problems.
Benefits of Hiring a CDSCO Loan Licence Consultant
Professional consulting can help businesses with:
- Loan Licence applicability
- Product regulatory assessment
- Drug classification
- Host manufacturer assessment
- Form 24A / 25A support
- Other applicable Loan Licence routes
- Schedule M GMP review
- Manufacturing agreement documentation
- Product documentation
- Application filing
- Inspection preparation
- Regulatory query response
- Product addition
- Post-approval compliance
This allows pharmaceutical companies to focus on product development and market strategy while the regulatory process is managed systematically.
Why Choose Green Permits for CDSCO Loan Licence Consulting?
Green Permits Consulting supports pharmaceutical manufacturers, startups, brand owners, healthcare companies, and businesses with drug licensing and industrial regulatory compliance across India.
Green Permits can assist with:
- CDSCO Loan Licence
- Drug Loan Licence
- Form 24A Application
- Form 25A Licence Support
- Product Regulatory Assessment
- New Drug Compliance Assessment
- Schedule M GMP Gap Assessment
- Host Manufacturer Review
- Manufacturing Agreement Documentation
- Inspection Preparation
- Drug Licence Query Response
- Product Addition
- Drug Manufacturing Licence
- Environmental and Factory Compliance
Our approach combines product assessment, manufacturing-facility review, GMP compliance, documentation, licensing, and post-approval support under one structured process.
Learn More About CDSCO Loan Licence for Pharma Manufacturers
If you are planning to manufacture pharmaceutical products using another licensed manufacturer's facility, a Loan Licence can help you enter or expand the market without immediately establishing a complete pharmaceutical manufacturing plant of your own.
Read more about CDSCO and pharmaceutical regulatory compliance services here:
π https://www.greenpermits.in/08/cdsco-loan-licence-consultant-pharma-cosmetics/
π Get Expert Assistance for CDSCO Loan Licence
If you need help with CDSCO Loan Licence for Pharma Manufacturers, Form 24A, Form 25A, host manufacturer assessment, Schedule M compliance, product documentation, inspection preparation, or regulatory filing, Green Permits Consulting can assist you.
π Website: www.greenpermits.in
π Phone: +91 78350 06182
π§ Email: wecare@greenpermits.in
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)